NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF). In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
“We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF. “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients. Dr. Oestreich brings a wealth of business development experience in biopharma and biotech that will play an invaluable role in the continued growth and impact of our fund.”
Dr. Oestreich has more than 20 years of diverse experience in business development and strategic alliances spanning large biopharma, biotech, and early academic research. Previously, she served as Chief Business Officer at the biotech Galecto and Vice President at the cell therapy company Mnemo Therapeutics. In addition, Dr. Oestreich was a Venture Partner at RA Capital and Executive Vice President at Evotec, where she built its North American investment arm and started an incubator with Samsara BioCapital. Her experience also includes work at F. Roche Hoffmann-La Roche Ltd., where she served as International Business Leader, and Novartis in Business Development and in Commercial.
“The MMRF has made a tremendous impact to help advance new therapies for myeloma patients and I am truly excited to join this effort as Managing Director of the MIF,” said Dr. Oestreich. “Through the MIF’s investment strategy, we will continue our work to advance the development of novel treatments and innovative therapeutic strategies for patients.”
In addition to her role at the MIF, Dr. Oestreich currently serves on the boards of the German American Business Council in Boston and the Harvard Kennedy School’s Women’s Network and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of the Launchpad Venture Group, an advisor at grIP Venture Studio to Biognosys (a Bruker company), Invitris, CART company CelineTx, and to the drug development and investment company OrangeGrove Bio. She is also a member of the W20 Entrepreneurship task force, the official engagement group of the G20.
To learn more about the MIF, visit www.myelomainvestmentfund.org.
About the Myeloma Investment Fund (MIF)
The Myeloma Investment Fund (MIF) is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.